For personal use. Only reproduce with permission from The Lancet Publishing Group. To test this idea, the researchers treated their monkeys with BP 897, a partial D 3 receptor agonist. BP 897, explains Bézard, "slightly promotes the action of levodopa when there is a small amount of the drug in the system but acts as an antagonist when there is too much levodopa as in dyskinesia". As hoped, the partial agonist normalised D 3 receptor function and thus attenuated the side-effects of levodopa treatment (Nat Med; published online May 12; DOI 10.1038/nm875).
"Although I would like to see more data on different drug doses, the implications of this study are that in patients who have developed dyskinesia as a result of levodopa treatment, a D 3 receptor partial agonist at the right dose should decrease involuntary movement while having no adverse effect on the beneficial actions of levodopa", comments Jenner. But, he warns, "whether this can be achieved in practice is a different story".
A phase 2A clinical trial already initiated in France should start to address this reservation.
Jane Bradbury

Therapy found for Parkinson's disease dyskinesia Coronavirus confirmed as cause of SARS
A n international team of researchers has completed the final proofs that severe acute respiratory syndrome (SARS) is caused by the primary suspect-SARS-associated coronavirus (SCV).
Health officials hope that the confirmation will make the task of containing the epidemic more manageable.
Tests done over the past 2 months have shown that SARS-associated coronavirus fulfils three of Koch's six postulates that must be satisfied to establish a virus as the cause of a disease: isolation from the host, cultivation in host cells, and filterability.
New research has shown that the virus fulfills the three remaining criteria: production of similar disease in the host species or a closely related species-in this case macaques; reisolation of the virus from infected test individuals; and detection of an immune response to infection with the virus (Nature 2003; 423: 240).
Lead researcher Albert Osterhaus (Erasmus Medical Centre, Rotterdam, Netherlands) said that the confirmation of the role of the virus was a tremendous collaborative effort. "Confirmation of the causative role of SCV in the macaque experiment came within 3 weeks after the virus had first been found and implicated as the possible cause of SARS", he said. "This rapid turnaround was made possible by the exemplary coordination of all the scientific efforts through the WHO network of laboratories involved."
Trish Perl (Johns Hopkins School of Medicine, Baltimore, MD, USA) compared the speed with which SCV was confirmed as the cause of SARS to the time it took to confirm HIV as the cause of AIDS-nearly 2 years in the latter case. "The rapidity of discovery, identification and fulfillment of Koch's [postulates] is astonishing", said Perl.
The confirmation of SCV's role in SARS will have a substantial effect on efforts to control the disease, said Alison Galvani (University of California, Berkeley, CA, USA). "The identification and genetic sequencing of the causative agent of SARS does have implications for the control of this disease both in the short term and in the long term", she said. "The PCR assay can be used as a diagnostic test to identify people who are incubating the disease but are not yet symptomatic. This will enable us to develop much more efficient quarantine procedures of only the people who have been infected, rather than everyone who may have been exposed."
David Lawrence
Science Photo Library
Rights were not granted to include this image in electronic media. Please refer to the printed journal.
